> Ask the expert: Triple-negative breast cancer with Elaine Walsh, MB BCh BAO, PhD

Ask the expert: Triple-negative breast cancer

Elaine Walsh, MB BCh BAO, PhD

Date and Time

Wed, Jul 21, 2021 7:00 pm to 8:00 pm ET

Location

Virtual

Watch session recording

Event details

Making up 15 to 20 percent of all breast cancer diagnoses, triple-negative breast cancer (TNBC) is often seen as a more aggressive subtype that disproportionally affects young, Black, and Latinx communities.

Oncologist Elaine Walsh, MB BCh BAO, PhD answers questions about TNBC symptoms, side-effects, and treatment options for early stage and metastatic breast cancer.

Date and Time

Wed, Jul 21, 2021 7:00 pm to 8:00 pm ET

Location

Virtual

Watch session recording
speakers_feature

About our expert

Elaine Walsh, MB BCh BAO, PhD

Elaine Walsh, MB BCh BAO, PhD, is a medical oncologist who specializes in the treatment of people with breast cancer. At Memorial Sloan Kettering Cancer Center, Dr. Walsh works as part of a multidisciplinary team to provide the highest level of care and best treatment options to people with breast cancer, while taking individual preferences and priorities into account.

3 Tier Sponsors

Event sponsors

Presenting organizational partner

Signature

upcoming_events

Upcoming Events

Ask the expert: Metastatic breast cancer

Wed, Dec 14, 2022

Learn More

Thriving Together: 2023 Conference on Metastatic Breast Cancer

Fri, Apr 28, 2023

Learn More
related_resources_article_carousel

Related articles

Triple-negative

05/05/22 | BY: Reshma L. Mahtani

While some breast cancers express hormone receptors or have too many copies of the HER2 gene, other breast cancers may not have these characteristics. Triple-negative breast cancers (TNBC) do not express estrogen receptors, progesterone receptors, or HER2 receptors. About 10% to 15% of breast cancers are triple-negative.

Read More | 13 Min. Read

Triple-negative metastatic breast cancer

05/04/22 | BY: Rita Nanda

Metastatic triple-negative breast cancer is a rare form of aggressive breast cancer. Learn more its symptoms, diagnosis, and treatment options.

Read More | 11 Min. Read

Sacituzumab govitecan

12/15/20 | BY: Stephanie Graff

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people with metastatic, triple-negative breast cancer.

Read More | 5 Min. Read

Follow-up care for TNBC

04/18/18 | BY: Lisa Carey

Learn what follow-up care may be needed and what it entails following a treatment for triple-negative breast cancer.

Read More | 4 Min. Read |

Dealing with negative comments

04/18/18 | BY: Lisa Carey

Get tips on how to manage people who have opinions about your breast cancer treatment.

Read More | 6 Min. Read

Risks and fear of recurrence

04/18/18 | BY: Lisa Carey

Find out about activities and emotional support to help quell anxiety and worry after treatment for triple-negative breast cancer. 

Read More | 3 Min. Read
stay_connected

Stay Connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.

[item.name]
[item.name]
[item]
[item]
[class^="wpforms-"]
[class^="wpforms-"]
[item.name]
[item.name]
[item]
[item]